Cure My Disease

Don't miss your cure!

 Log in / Sign up

Second chance: drug retrial offers hope for patients whose blood disorder returned

NCT ID NCT07039422

Recruiting now Disease control Sponsor: Novartis Pharmaceuticals Source: ClinicalTrials.gov ↗

Summary

This study is testing whether a second course of the drug ianalumab can safely help control two rare blood disorders—ITP and wAIHA—in adults who benefited from it before but later relapsed. It will enroll about 60 people who previously participated in related ianalumab trials. The main goal is to see if the drug can prevent treatment failure in ITP and restore a durable response in wAIHA over several months.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PRIMARY IMMUNE THROMBOCYTOPENIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-••••

Locations

  • Novartis Investigative Site

    RECRUITING

    Roeselare, West-Vlaanderen, 8800, Belgium

  • Novartis Investigative Site

    RECRUITING

    Guangzhou, Guangdong, 510515, China

  • Novartis Investigative Site

    RECRUITING

    Ostrava, Poruba, 708 52, Czechia

  • Novartis Investigative Site

    RECRUITING

    Florence, FI, 50134, Italy

  • Novartis Investigative Site

    RECRUITING

    Vicenza, VI, 36100, Italy

  • Novartis Investigative Site

    RECRUITING

    George Town, 10050, Malaysia

  • Novartis Investigative Site

    RECRUITING

    Singapore, 119074, Singapore

  • Novartis Investigative Site

    RECRUITING

    Samsun, Atakum, 55200, Turkey (Türkiye)

  • Novartis Investigative Site

    RECRUITING

    London, W12 0HS, United Kingdom

Conditions

Explore the condition pages connected to this study.

PRIMARY IMMUNE THROMBOCYTOPENIA WARM AUTOIMMUNE HEMOLYTIC ANEMIA